The goal of this program is to enhance nurses’ and dietitians’ ability to care for patients taking new injectable classifications of medications for diabetes. After studying the information presented here, you will be able to:
- Describe the roles of amylin and the human incretin hormone glucagon-like-peptide-1 in regulating blood glucose levels
- Explain three benefits of GLP-1 receptor agonists and amylin analog injection therapy
- Discuss three nursing interventions to help patients adjust to and properly use GLP-1 receptor agonists or amylin analog therapy
This course is intended for multiple professions, including dietitians, health educators, and nurses.
Dietitians: Take this version of the course to ensure you receive appropriate credit.
For the version accredited or approved for another profession, go to your specific profession at www.continuingeducation.com
. If you have a CE Direct login ID and password (generally provided by your employer), please log in as you normally would at lms.nurse.com
and search for this topic title.
ContinuingEducation.com is a Continuing Professional Education (CPE) Accredited Provider (#GD001) with the Commission on Dietetic Registration (CDR). This course is a Level 2 course. Suggested CDR Learning Codes:3000, 3070, 4000, 4040, 5000, 5190, 5290, 5370, 5390
ContinuingEducation.com is also accredited by the Florida Council of Dietetics and Nutrition (provider # FBN 50-1489).
This program has been approved for fulfilling the continuing education requirements of the Certifying Board for Dietary Managers (CBDM). Granting prior approval does not constitute endorsement of the program content or its program sponsor.